The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty

• Published in: Clinical and experimental pediatrics 2017, 60(12), , pp.395-402
• Main Authors: Yoon, Jong Wan, Park, Hyun A, Lee, Jieun, Kim, Jae Hyun
• Format: Article
• Language: English
• Subjects: Abdomen; Age; Body mass index; Gonadotropin-releasing hormone agonist; Obesity; Original; Overweight; Precocious puberty; Puberty; Regression analysis; 소아과학
• ISSN: 1738-1061; 2092-7258; 2713-4148
• DOI: 10.3345/kjp.2017.60.12.395

The potential effect of gonadotropin-releasing hormone agonist (GnRHa) treatment on the weight of girls with central precocious puberty (CPP) remains a controversy. We investigated anthropometric changes during and after GnRHa treatment among girls with CPP. This retrospective study evaluated data from 127 girls with CPP who received GnRHa treatment for ≥2 years. Height, weight, and body mass index (BMI) values were compared at the baseline (visit 1), after 1 year of GnRHa treatment (visit 2), the end of GnRHa treatment (visit 3), and 6-12 months after GnRHa discontinuation (visit 4). The height score for chronological age (CA) increased continuously between visit 1 and visit 4. No significant differences were observed in BMI score for CA between visits 1 and 4. However, an increasing trend in the BMI score for bone age (BA) was observed between visits 1 and 4. The numbers of participants who were of normal weight, overweight, and obese were 97, 22, and 8, respectively, at visit 1, compared to 100, 16, and 11, respectively, at visit 4 ( =0.48). Among girls with CPP, the overall BMI z score for CA did not change significantly during or after GnRHa treatment discontinuation, regardless of their BMI status at visit 1. However, the BMI z score for BA showed an increasing trend during GnRHa treatment and a decreasing trend after discontinuation. Therefore, long-term follow-up of BMI changes among girls with CPP is required until they attain adult height.